339370-40-0

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-2-fluorobenzenesulphonyl chloride 98% is used as a reagent for the synthesis of complex molecules in the pharmaceutical industry. Its unique structure and high reactivity allow for the creation of a wide range of pharmaceutical compounds, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Bromo-2-fluorobenzenesulphonyl chloride 98% serves as a precursor in the production of various agrochemicals. Its versatility in chemical reactions enables the synthesis of molecules with potential applications in crop protection, pest control, and other agricultural areas.
Used in Organic Synthesis:
5-Bromo-2-fluorobenzenesulphonyl chloride 98% is utilized as a versatile reagent in organic synthesis for the preparation of a variety of organic compounds. Its high purity and reactivity make it an ideal choice for chemists working on the development of new chemical entities and the optimization of existing synthetic routes.
Used in Research and Development:
5-Bromo-2-fluorobenzenesulphonyl chloride 98% is employed in research and development settings to explore its potential applications in various chemical reactions and processes. Its unique properties and high purity level make it a valuable tool for scientists investigating new methods and techniques in organic chemistry.
Used in Production of Other Important Chemicals:
5-Bromo-2-fluorobenzenesulphonyl chloride 98% is used as a precursor in the synthesis of other important chemicals, further expanding its utility in the chemical industry. Its ability to participate in a wide range of reactions makes it a key component in the production of various specialty chemicals and intermediates.

Upstream product

• 460-00-4 1-Bromo-4-fluorobenzene 
• 2924-09-6 5-bromo-2-fluoroaniline 

Downstream Products

• 1558011-58-7 5-bromo-2-fluoro-N-[3-fluoro-4-({6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinolin-4-yl}oxy)phenyl]benzenesulfonamide 
• 1643915-62-1 4-(5-bromo-2-fluorophenylsulfonyl)morpholine 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS

Provided herein is a compound of formula (XXXII) or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer thereof or a physiologically functional derivative thereof, wherein R1, R2, R3, G, A, E, n, p, and q are defined herein. Also provided herein are compositions comprising a compound of formula (XXXII), and methods of using a compound of formula (XXXII), e.g., in the treatment or prevention of skin disorders.

Benzothiadiazine compound, application thereof and positron drug of AMPAR

The invention relates to a benzothiadiazine compound, application thereof and a positron drug of AMPAR (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor). The structure of the benzothiadiazine compound is shown as the specification, wherein R is selected from one of Br, Cl, F, I and the groups shown as the specification. A marked benzothiadiazine compound prepared by taking the above benzothiadiazine compound as a precursor has high standard uptake value and high specificity to AMPAR.

Radiosynthesis and preliminary evaluation of 11C-labeled 4-cyclopropyl-7-(3-methoxyphenoxy)-3,4-dihydro-2H-benzo[e] [1,2,4] thiadiazine 1,1-dioxide for PET imaging AMPA receptors

The α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) belong to the family of ionotropic transmembrane receptors for glutamate (iGluRs) that are implicated in the pathology of neurological disorders and neurodegenerative diseases. Inspired by a recently developed positive allosteric modulator of AMPARs, 4-cyclopropyl-7-(3-methoxyphenoxy)-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide (16; EC50 = 2.0 nM), we designed a new synthetic route for N-protected phenolic precursor 13 and efficiently radiolabeled a PET ligand [11C]AMPA-1905 ([11C]16) using a modified one-pot two-step strategy in high radiochemical yield and high molar activity. Preliminary in vivo evaluation was carried out to investigate the suitability of [11C]16 as a potential PET probe for AMPAR imaging.

SUBSTITUTED QUINOLINES AND METHODS FOR TREATING CANCER

Substituted quinoline compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors

The phosphoinositide 3-kinases (PI3Ks) have been linked to an extraordinarily diversified group of cellular functions making these enzymes compelling targets for the treatment of disease. A large body of evidence has linked PI3Kγ to the modulation of autoimmune and inflammatory processes making it an intriguing target for drug discovery. Our high-throughput screening (HTS) campaign revealed two hits that were nominated for further optimization studies. The in vitro activity of the first HTS hit, designated as the sulfonylpiperazine scaffold, was optimized utilizing structure-based design. However, nonoptimal pharmacokinetic properties precluded this series from further studies. An overlay of the X-ray structures of the sulfonylpiperazine scaffold and the second HTS hit within their complexes with PI3Kγ revealed a high degree of overlap. This feature was utilized to design a series of hybrid analogues including advanced leads such as 31 with desirable potency, selectivity, and oral bioavailability.